# A Novel Statistic for Genome-Wide Interaction Analysis

Xuesen Wu<sup>1</sup>, Hua Dong<sup>2</sup>, Li Luo<sup>3</sup>, Yun Zhu<sup>3</sup>, Gang Peng<sup>3</sup>, John D. Reveille<sup>4</sup>, Momiao Xiong<sup>3</sup>\*

1 Department of Epidemiology and Statistics, Bengbu Medical College at Bengbu, Anhui, China, 2 Laboratory of Theoretical Systems Biology and Center for Evolutionary Biology, State Key Laboratory of Genetic Engineering, School of Life Science and Institute for Biomedical Sciences, Fudan University, Shanghai, China, 3 Human Genetics Center, University of Texas School of Public Health, Houston, Texas, United States of America, 4 Division of Rheumatology, Medical School, University of Texas Health Science Center at Houston, Houston, Texas, United States of America

#### **Abstract**

Although great progress in genome-wide association studies (GWAS) has been made, the significant SNP associations identified by GWAS account for only a few percent of the genetic variance, leading many to question where and how we can find the missing heritability. There is increasing interest in genome-wide interaction analysis as a possible source of finding heritability unexplained by current GWAS. However, the existing statistics for testing interaction have low power for genome-wide interaction analysis. To meet challenges raised by genome-wide interactional analysis, we have developed a novel statistic for testing interaction between two loci (either linked or unlinked). The null distribution and the type I error rates of the new statistic for testing interaction are validated using simulations. Extensive power studies show that the developed statistic has much higher power to detect interaction than classical logistic regression. The results identified 44 and 211 pairs of SNPs showing significant evidence of interactions with FDR<0.001 and 0.001<FDR<0.003, respectively, which were seen in two independent studies of psoriasis. These included five interacting pairs of SNPs in genes LST1/NCR3, CXCR5/BCL9L, and GLS2, some of which were located in the target sites of miR-324-3p, miR-433, and miR-382, as well as 15 pairs of interacting SNPs that had nonsynonymous substitutions. Our results demonstrated that genome-wide interaction analysis is a valuable tool for finding remaining missing heritability unexplained by the current GWAS, and the developed novel statistic is able to search significant interaction between SNPs across the genome. Real data analysis showed that the results of genome-wide interaction analysis can be replicated in two independent studies.

Citation: Wu X, Dong H, Luo L, Zhu Y, Peng G, et al. (2010) A Novel Statistic for Genome-Wide Interaction Analysis. PLoS Genet 6(9): e1001131. doi:10.1371/journal.pgen.1001131

Editor: Nicholas J. Schork, University of California San Diego and The Scripps Research Institute, United States of America

Received February 26, 2010; Accepted August 20, 2010; Published September 23, 2010

**Copyright:** © 2010 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** The project described was supported by Grant 1R01AR057120 # 01, P01 AR052915-01A1, and P50 AR054144-01 CORT from the National Institutes of Health and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Funding support for Collaborative Association Study of Psoriasis was provided by the Foundation for the National Institutes of Health (GAIN Program), and the genotyping of samples was provided through the Genetic Association Information Network (GAIN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

1

Competing Interests: The authors have declared that no competing interests exist.

\* E-mail: Momiao.Xiong@uth.tmc.edu

#### Introduction

In the past three years, about 400 genome-wide association studies (GWAS) that focused largely on individually testing the associations of single SNP with diseases have been conducted [1]. These studies have identified more than 531 SNPs associated with different traits or diseases [2] and have provided substantial information for understanding disease mechanisms. Despite the progress that has been made, the significant SNP associations identified by GWAS account for only a few percent of the genetic variance which begs the question where and how the missing heritability can be identified [3,4]. Possible explanations include [1,4]:

(1) The previous GWAS are mainly based on the common disease, common variant hypothesis. However, in addition to single nucleotide polymorphisms (SNPs) with a minor allele frequency (MAF) greater than 1%, there are other classes of human genetic variation including: (a) rare variants that are defined as mutations with a MAF of less than 1% and (b) structural variants including copy number variants (CNVs) and copy neutral variation such as inversions and translocations. Common diseases can also be caused by multiple rare mutations, each with a low marginal genetic effect. A more

- realistic model is that the entire spectrum of genetic variants ranging from rare to common contributes to disease susceptibility.
- (2) Most of current GWAS have focused on SNP analysis in which each variant is tested for association individually. However, common disease often arises from the combined effect of multiple loci within a gene or interaction of multiple genes within a pathway. If we only consider the most significant SNPs, the genetic variants that jointly have significant impact on risk, but individually make only a small contribution, will be missed.
- (3) The power of the widely used statistics for detection of genegene interaction and gene-environment interactions is low. Many interacting SNPs have not been identified.

Another way to discover the missing heritability of complex diseases is to investigate gene-gene and gene-environment interaction. Disease development is a dynamic process of gene-gene and gene-environment interactions within a complex biological system which is organized into interacting networks [5]. Modern complexity theory assumes that the complexity is attributed to the interactions among the components of the system, therefore, interaction has been considered as a sensible measure of

### **Author Summary**

It is expected that genome-wide interaction analysis can be a possible source of finding heritability unexplained by current GWAS. However, the existing statistics for testing interaction have low power for genome-wide interaction analysis. To meet challenges raised by genome-wide interactional analysis, we develop a novel statistic for testing interaction between two loci (either linked or unlinked) and validate the null distribution and the type I error rates of the new statistic through simulations. By extensive power studies we show that the developed novel statistic has much higher power to detect interaction than the classical logistic regression. To provide evidence of gene-gene interactions as a possible source of the missing heritability unexplained by the current GWAS, we performed the genome-wide interaction analysis of psoriasis in two independent studies. The preliminary results identified 44 and 211 pairs of SNPs showing significant evidence of interactions with FDR<0.001 and 0.001 < FDR < 0.003, respectively, which were common in two independent studies. These included five interacting pairs of SNPs, some of which were located in the target sites: LST1/NCR3, CXCR5/BCL9L and GLS2 of miR-324-3p, miR-433, and miR-382, and 15 pairs of interacting SNPs that had nonsynonymous substitutions.

complexity of the biological systems. The more interactions between the components there are, the more complex the system is. The disease may be caused by joint action of multiple loci. Motivation for studying statistical interaction is to provide increased power for detecting joint acting effects of interacting loci than testing for only marginal association of each of the loci individually. Screening for only main effects might miss the vast majority of the genetic variants that interact with each other and with environment to cause diseases [6]. We argue that the interactions hold a key for dissecting the genetic structure of complex diseases and elucidating the biological and biochemical pathway underlying the diseases [7,8]. Ignoring gene-gene and gene-environment interactions will likely obscure the detection of genetic effects and may lead to inconsistent association results across studies [9,10].

GWAS in which several hundred thousands or even a millions of SNPs are typed in thousands of individuals provide unprecedented opportunities for systematic exploration of the universe of variants and interactions in the entire genome and also raise several serious challenges for genome-wide interaction analysis. The first challenge comes from the problems imposed by multiple testing. Even for investigating pair-wise interaction, the total number of tests for interaction between all possible SNPs across the genome will be extremely large. Bonferroni-corrected P-values for ensuring genome-wide significance level of 0.05 will be too small to reach. The second challenge is the need for computationally simple statistics for testing interactions. The simplest way to search for interactions between two loci is to test all possible two-locus interactions. This exhaustive search demands large computations. Therefore, the computational time of each twolocus interaction test should be short. The third challenge is the power of the statistics for testing interaction. To ensure the genome-wide significance, the statistics should have high power to detect interaction. Developing simple and efficient analytic methods for evaluation of the gene-gene interactions is critical to the success of genome-wide gene-gene interaction analysis. Finally, the fourth challenge is replication of the finding of such interactions in independent studies.

This report will attempt to meet these challenges, at least in part. To achieve this, we first should define a good measure of gene-gene interaction. Despite current enthusiasm for investigation of genegene interactions, published results that document these interactions in humans are limited and the essential issue of how to define and detect gene-gene interactions remains unresolved. Over the last three decades, epidemiologists have debated intensely about how to define and measure interaction in epidemiologic studies [7,8,11– 15]; The concept of gene-gene interactions is often used, but rarely specified with precision [16]. In general, statistical gene-gene interaction is defined as departure from additive or multiplicative joint effects of the genetic risk factors [17]. It is increasingly recognized that statistical interactions are scale dependent [18]. In other words, how to define the effects of a risk factor and how to measure departure from the independence of effects will greatly affect assessment of gene-gene interaction. The most popular scale upon which risk factors are measured in case-control studies is oddsratio. The traditional odds-ratio is defined in terms of genotypes at two loci. Similar to two-locus association analysis where only genotype information at two loci is used, odds-ratio defined by genotypes for testing interaction will not employ allelic association information. However, it is known that interaction between two loci will generate allelic associations in some circumstances [19]. Since they do not use allelic association information between two loci, the statistical methods based on the odds-ratio that is defined in terms of genotypes will have less power to detect interaction. To overcome this limitation, we will define odds-ratio in terms of a pseudohaplotype (which is defined as two alleles located on the same paternal or maternal chromosomes) for measuring interaction, and then we will investigate its properties and develop a statistic based on pseudohaplotype defined odds-ratio for testing interaction between two loci (either linked or unlinked).

To demonstrate that the pseudohaplotype odds-ratio interaction measure-based statistic for detection of interaction between two loci will not cause false positive problems, we then investigate type I error rates. To reveal the merit and limitation of the pseudohaplotype odds-ratio interaction measure-based statistic for detection of interaction, we will compare its power for detecting interaction with the traditional logistic regression and "fast-epistasis" in PLINK [20].

Although nearly 400 GWAS have been documented, few genome-wide interaction analyses have been performed and few findings of significant interaction reported [8,21,22]. Emily et al [23] tested about 3,107,904-3,850,339 pairs of SNPs located in genes with potential protein-protein interaction and reported four significant cases of interactions, one in each of Crohn's Disease, bipolar disorder, hypertension and rheumatoid arthritis in the WTCCC dataset, but these have not been replicated. To further evaluate the performance of our new statistic and test the feasibility of genome-wide interaction analysis, the presented statistic was applied to interaction analysis of two independent GWAS datasets of psoriasis where 1,266,378,301 pairs of SNPs from 50,327 SNPs in the first dataset and 1,243,782,750 pairs of SNPs from 49,876 SNPs in the second dataset were tested for interactions. These SNPs in the datasets were selected from 501 pathways assembled from KEGG [24] and Biocarta (http://www. biocarta.com) pathway databases. A program for using the developed statistic to test interaction which was implemented by C++ can be downloaded from our website http://www.sph.uth. tmc.edu/hgc/faculty/xiong/index.htm.

### Methods

A case-control study design for detection of interaction between two loci (SNPs) where two loci can be either linked or unlinked

were considered. The statistics for testing interaction are usually motivated by the measure of interaction. The widely used logistic regression methods for detection of gene-gene interaction are based on then odds-ratio measure of interaction. Traditional additive and multiplicative odds ratio measures of interaction are defined in terms of genotypes at two loci. In this report, a novel statistic for testing interaction between two loci is based on multiplicative odds-ratio measures defined in terms of pseudohaplotypes. For the convenience of presentation, we first briefly introduce the odds ratio interaction measure in terms of genotypes, alleles, and then present the odds ratio measure in terms of pseudohaplotypes.

## Genotype-Based Odds Ratio Multiplicative Interaction Measure

Consider two loci: G and H. Assume that the codes G=1(G=0) and H=1(H=0) denote whether an individual is a carrier (non-carrier) of the susceptible genotypes at the loci G and H, respectively. Let D denote disease status where D=1(D=0) indicates an affected (unaffected) individual. Consider the following logistic model:

$$P(D=1|G,H) = \frac{e^{\alpha+\beta_G G + \beta_H H + \beta_{GH} GH}}{1 + e^{\alpha+\beta_G G + \beta_H H + \beta_{GH} GH}}.$$
 (1)

The odds-ratio associated with G for nonsusceptible genotype at the locus H (H=0) is defined as

$$OR_G = \frac{P(D=1|G=1,H=0)/P(D=0|G=1,H=0)}{P(D=1|G=0,H=0)/P(D=0|G=0,H=0)}.$$

Similarly, the odds-ratio associated with H for nonsusceptible genotype at the locus G (G=0) is defined as

$$OR_H = \frac{P(D=1|G=0,H=1)/P(D=0|G=0,H=1)}{P(D=1|G=0,H=0)/P(D=0|G=0,H=0)}$$

The odds-ratio associated with susceptibility at G and H compared to the baseline category G=0 and H=0 is then computed as

$$OR_{GH} = \frac{P(D=1|G=1,H=1)/P(D=0|G=1,H=1)}{P(D=1|G=0,H=0)/P(D=0|G=0,H=0)}.$$

The odds for baseline category G=0 and H=0 are determined as

$$OR_b = \frac{P(D=1|G=0,H=0)}{P(D=0|G=0,H=0)}$$

From equation (1), we clearly have

$$OR_b = e^{\alpha}, OR_G = e^{\beta G}, OR_H = e^{\beta H}$$
 and  $OR_{GH} = OR_G OR_H e^{\beta GH}$ .

Define a multiplicative interaction measure between two loci G and H as

$$I_{GH} = \log \frac{OR_{GH}}{OR_G OR_H}.$$
 (2 - A)

It is clear that

$$\beta_{GH} = I_{GH}. \tag{2 - B}$$

If  $OR_{GH} = OR_GOR_H$ , i.e., there is no interaction between loci G and H, then  $I_{GH} = 0$ . This shows that the logistic regression coefficient for interaction term  $\beta_{GH}$  is equivalent to the interaction measure defined as log odds-ratio. The interaction measure  $I_{GH}$ can also be written as

$$\begin{split} I_{GH} = & \log \frac{P(G=1, H=1|D=1)P(G=0, H=0|D=1)}{P(G=1, H=0|D=1)P(G=0, H=1|D=1)} - \\ & \log \frac{P(G=1, H=1|D=0)P(G=0, H=0|D=0)}{P(G=1, H=0|D=0)P(G=0, H=1|D=0)} \,. \end{split}$$

The values of odds-ratio defined in terms of genotypes depends on how to code indicator variables G and H. Suppose that alleles  $G_1$ and  $H_1$  are alleles that increase disease risk. For a recessive model, G is coded as 1 if the genotype is  $G_1G_1$ , otherwise, G is coded as 0. For a dominant model, G is coded as 1 if the genotypes are either  $G_1G_1$  or  $G_1G_2$ , otherwise G is coded as 0. The indicator variable H can be similarly coded. However, in real data analysis, the disease models are unknown. Especially, the types of two-locus disease models are large [25]. We may have a large number of possible coding, and many of them may have larger numbers of degrees of freedom than the allelic model.

# Allele-Based Odds Ratio Multiplicative Interaction Measure

Similar to the odds ratio for genotypes, we can define odds-ratio in terms of alleles. Let  $P(D=1|G_i,H_i)$  be the probability that an individual becomes affected given they have genotype  $G_i/G_k$  at locus G and  $H_i/H_I$  at locus H, where  $G_k$  is either  $G_1$  or  $G_2$  (i.e.  $G_k$ is a member of the set  $\{G_1,G_2\}$ ) and  $H_I$  is either  $H_1$  or  $H_2$  (i.e.  $H_I$ is a member of the set  $\{H_1,H_2\}$ ). We can similarly define  $P(D=0|G_i,H_i)$ . We then can determine the odds-ratio associated with the allele  $G_1$  at the G locus and allele  $H_1$  at the H locus compared to the baseline  $G_2/H_2$  as

$$OR_{G_1/H_1} = \frac{P(D=1|G_1, H_1)}{P(D=0|G_1, H_1)} \cdot \frac{P(D=1|G_2, H_2)}{P(D=0|G_2, H_2)}.$$

Similarly, we measure the odds-ratio associated with the alleles  $G_1/H_2$  and  $G_2/H_1$ , respectively as

$$OR_{G_1/H_2} = \frac{\frac{P(D=1|G_1,H_2)}{P(D=0|G_1,H_2)}}{\frac{P(D=1|G_2,H_2)}{P(D=0|G_2,H_2)}} \text{ and } OR_{G_2/H_1} = \frac{\frac{P(D=1|G_2,H_1)}{P(D=0|G_2,H_2)}}{\frac{P(D=0|G_2,H_2)}{P(D=0|G_2,H_2)}}$$

Similar to genotype, we can define a multiplicative interaction measure in terms of log odds-ratio for allele as

$$I_{G/H} = \log \frac{OR_{G_1/H_1}}{OR_{G_1/H_2}OR_{G_2/H_1}}$$

which is equivalent to

$$\begin{split} &I_{G/H} = \log(R) - \log(S), \text{ where} \\ &R = \frac{P(G_1, H_1 | D = 1)P(G_2, H_2 | D = 1)}{P(G_1, H_2 | D = 1)P(G_2, H_1 | D = 1)} \text{ and} \\ &S = \frac{P(G_1, H_1 | D = 0)P(G_2, H_2 | D = 0)}{P(G_1, H_2 | D = 0)P(G_2, H_1 | D = 0)}. \end{split}$$



The "fast-epistasis" test statistic in PLINK (http://pngu.mgh. harvard.edu/~purcell/plink/index.shtml) is defined as

$$Z = \frac{\log(R) - \log(S)}{\sqrt{SE(R) + SE(S)}},$$

where SE(R) and SE(S) denote the standard deviation of R and S, respectively. Absence of interaction is implied if and only if

$$\frac{P(G_1, H_1|D=1)P(G_2, H_2|D=1)}{P(G_1, H_2|D=1)P(G_2, H_1|D=1)} = \frac{P(G_1, H_1|D=0)P(G_2, H_2|D=0)}{P(G_1, H_2|D=0)P(G_2, H_1|D=0)}$$

This is the basis of the "fast-epistasis" test in PLINK.

# Haplotype-Based Odds Ratio Multiplicative Interaction Measure

Suppose that the locus G has two alleles  $G_1$  and  $G_2$  and the locus H has two alleles  $H_1$  and  $H_2$ . Let  $P_{G_1}^A, P_{G_2}^A, P_{H_1}^A, P_{H_2}^A$  and  $P_{G_1}^N, P_{G_2}^N, P_{H_1}^N, P_{H_2}^N$  be the frequencies of the alleles  $\tilde{G}_1, \tilde{G}_2, H_1, H_2$  in the cases and controls, respectively. For the discussion of convenience, we introduce a terminology of "pseudohaplotype". When two loci are linked, a pseudohaplotype is defined as the regular haplotype. When two loci are unlinked, a pseudohaplotype is defined as a set of alleles that are located in the same paternal or maternal chromosomes. The frequencies of a pseudohaplotype can be estimated by the classical methods for estimation of haplotype frequencies such as Expectation Maximization (EM) Algorithms. For simplicity, hereafter we will not make distinction between the haplotype and pseudohaplotype. When two loci are unlinked, a haplotype is understood as a pseudohaplotype. Let  $P_{11}^A, P_{12}^A, P_{21}^A, P_{22}^A$  and  $P_{11}^N, P_{12}^N, P_{21}^N, P_{22}^N$  denote the frequencies of haplotypes  $G_1H_1, G_1H_2, G_2H_1$  and  $G_2H_2$  in the cases and controls, respectively. We define a penetrance of the haplotype  $G_iH_i$  as the probability that an individual becomes affected given they have phased genotype  $G_iH_i/G_kH_l, k=1,2,l=1,2$ . Let  $f_{ijkl}$  be the penetrance of an individual with the genotype  $G_iH_i/G_kH_l$ ,  $h_{11}, h_{12}, h_{21}$  and  $h_{22}$  be the penetrance of the haplotypes  $G_1H_1,G_1H_2,G_2H_1$  and  $G_2H_2$ , respectively. The penetrance of the haplotype  $G_iH_i$  can be mathematically defined as

$$h_{ij} = P_{11}f_{ij11} + P_{12}f_{ij12} + P_{21}f_{ij21} + P_{22}f_{ij22},$$

where  $P_{11}, P_{12}, P_{21}$  and  $P_{22}$  are the population frequencies of the haplotypes  $G_1H_1, G_1H_2, G_2H_1$  and  $G_2H_2$ , respectively.

G=i and H=j represent a genotype coding scheme. Their represented genotypes depend on the specific genotype coding scheme. It should be noted that the haplotype  $G_iH_i$  and G=i and H=j have different meanings. By the same idea in defining genotype-based odds ratio in terms of penetrance of combinations of genotypes, we can determine the odds-ratio associated with the haplotypes  $G_1H_1$  compared to the baseline haplotype  $G_2H_2$  in terms of penetrance of the haplotypes as

$$OR_{G_1H_1} = \frac{h_{11}/(1-h_{11})}{h_{22}/(1-h_{22})}$$

Similarly, we calculate the odds-ratio associated with the

haplotypes  $G_1H_2$  and  $G_2H_1$ , respectively, as

$$OR_{G_1H_2} = \frac{h_{12}/(1-h_{12})}{h_{22}/(1-h_{22})}$$
 and 
$$OR_{G_2H_1} = \frac{h_{21}/(1-h_{21})}{h_{22}/(1-h_{22})}.$$

It is noted that replacing G = i and H = j in the definition of oddsratio in terms of genotypes by  $G_iH_i$  leads to the definition of oddsratio based on the haplotypes. However, the values and biological meanings of these two types of odds-ratios are different.

Similar to genotypes, we can compute a multiplicative interaction measure in terms of log odds-ratio for haplotypes as

$$I_{GH}^{H} = \log \frac{OR_{G_1H_1}}{OR_{G_1H_2}OR_{G_2H_1}}.$$
 (3)

In the absence of interaction, we have

$$\begin{split} OR_{G_1H_1} &= OR_{G_1H_2}OR_{G_2H_1} \text{ or } \\ \frac{P(D=1|G_1H_1)P(D=1|G_2H_2)}{P(D=1|G_1H_2)P(D=1|G_2H_1)} &= \frac{P(D=0|G_1H_1)P(D=0|G_2H_2)}{P(D=0|G_1H_2)P(D=0|G_2H_1)}. \end{split}$$

The multiplicative odds-ratio interaction measure in equation (3) is defined by the penetrance of the haplotypes. From case-control data it is difficult to calculate the penetrance of the haplotypes. However, we can show that the multiplicative odds-ratio interaction measure in equation (3) can be reduced to (Text S1, Appendix A)

$$I_{GH}^{H} = \log \frac{P_{11}^{A} P_{22}^{A}}{P_{12}^{A} P_{21}^{A}} - \log \frac{P_{11}^{N} P_{22}^{N}}{P_{12}^{N} P_{21}^{N}}.$$
 (4)

There are many algorithms and software to infer the haplotype frequencies in cases and controls. Therefore, we can easily calculate the multiplicative odds-ratio interaction measure by equation (4). It can be seen from equation (4) that the absence of interaction between two loci occurs if and only if the ratio of

haplotypes frequencies  $\frac{P_{11}^A P_{22}^A}{P_{12}^A P_{21}^A}$  in the cases and the ratio of haplotypes frequencies  $\frac{P_{11}^N P_{22}^N}{P_{12}^N P_{22}^N}$  in the controls are equal.

To gain understanding the multiplicative odds-ratio interaction measure, we study several special cases.

**Case 1.** One of two loci is a marker. If we assume that the locus H is a marker and is not associated with disease, then we

$$P_{ii}^A = P(G_i|D=1)P(H_i|G_i)$$
 and  $P_{ii}^N = P(G_i|D=0)P(H_i|G_i)$ ,

which implies that

$$\begin{split} \frac{P_{11}^A P_{22}^A}{P_{12}^A P_{21}^A} &= \frac{P(G_1|D=1)P(G_2|D=1)P(H_1|G_1)P(H_2|G_2)}{P(G_1|D=1)P(G_2|D=1)P(H_2|G_1)P(H_1|G_2)} \\ &= \frac{P_{11}^N P_{22}^N}{P_{12}^N P_{21}^N}. \end{split}$$

Thus, we obtain  $I_{GH}^H = 0$ . In other words, if the locus H is a marker, there is no interaction between two loci G and H. The



interaction measure  $I_{GH}^H$  between two loci should be equal to zero. Hence, our multiplicative odds-ratio interaction measure correctly characterizes the marker case.

Case 2. Logistic regression interpretation.

We define two indicator variables:

$$G = \begin{cases} 1 & G_1 \\ 0 & G_2 \end{cases} \text{ and } H = \begin{cases} 1 & H_1 \\ 0 & H_2 \end{cases}.$$
 (5)

Then four haplotypes at two loci can be coded as follows:

	G	н
$G_1H_1$	1	1
G <sub>1</sub> H <sub>2</sub>	1	0
$G_2H_1$	0	1
$\begin{aligned} &G_1H_1\\ &G_1H_2\\ &G_2H_1\\ &G_2H_2 \end{aligned}$	0	0

It follows from the logistic regression model in equation (1) that

$$\begin{split} OR_{G_1H_2} &= e^{\beta G} = OR_G \\ OR_{G_2H_1} &= e^{\beta H} = OR_H \\ OR_{G_1H_1} &= e^{\beta G + \beta H + \beta GH} = OR_G OR_H e^{\beta GH}, \end{split}$$

where odds-ratios  $OR_G$  and  $OR_H$  are defined in terms of alleles, i.e.

$$OR_G = \frac{P(D=1|G_1)/P(D=0|G_1)}{P(D=1|G_2)/P(D=0|G_2)} \text{ and}$$

$$OR_H = \frac{P(D=1|H_1)/P(D=0|H_1)}{P(D=1|H_2)/P(D=0|H_2)}$$

Therefore, the haplotype multiplicative odds-ratio interaction measure  $I_{GH}^H$  is equal to  $I_{GH}^H = \beta_{GH}$ , which has the same form as that in equation (2-B). This indicates that if the coding for the genotypes in the genotype multiplicative odds-ratio interaction measure  $I_{GH}$  is replaced by the coding for the haplotypes in equation (5) then we can obtain the haplotype multiplicative oddsratio interaction measure.

#### **Test Statistics**

In the previous section we defined the haplotype multiplicative odds-ratio interaction measure, which can be estimated by haplotype frequencies in cases and controls. By the delta method, we can obtain the variance of the estimator of the haplotype oddsratio interaction measure [26]:

$$Var(\hat{I}_{GH}^{H}) = \frac{1}{2n_{A}} \left[ \frac{1}{\hat{P}_{11}^{A}} + \frac{1}{\hat{P}_{12}^{A}} + \frac{1}{\hat{P}_{21}^{A}} + \frac{1}{\hat{P}_{22}^{A}} \right] + \frac{1}{2n_{G}} \left[ \frac{1}{\hat{P}_{11}^{N}} + \frac{1}{\hat{P}_{12}^{N}} + \frac{1}{\hat{P}_{21}^{N}} + \frac{1}{\hat{P}_{22}^{N}} \right],$$

where  $n_A$  and  $n_G$  are the number of sampled individuals in cases and controls. By the standard asymptotic theory we can define the haplotype odds-ratio interaction measure-based statistic for testing interaction between two loci:

$$T_{IH} = \frac{\left(\hat{I}_{GH}^{H}\right)^{2}}{V\left(\hat{I}_{GH}^{H}\right)} = \begin{bmatrix} \log\frac{\hat{P}_{11}^{A}\hat{P}_{22}^{A}}{\hat{P}_{12}^{A}\hat{P}_{21}^{A}} - \log\frac{\hat{P}_{11}^{N}\hat{P}_{22}^{N}}{\hat{P}_{12}^{N}\hat{P}_{21}^{N}} \end{bmatrix}^{2}$$

$$\frac{1}{2n_{A}} \left[ \frac{1}{\hat{P}_{11}^{A}} + \frac{1}{\hat{P}_{12}^{A}} + \frac{1}{\hat{P}_{21}^{A}} + \frac{1}{\hat{P}_{21}^{A}} + \frac{1}{\hat{P}_{21}^{A}} + \frac{1}{\hat{P}_{22}^{A}} \right] + \frac{1}{2n_{G}} \left[ \frac{1}{\hat{P}_{11}^{N}} + \frac{1}{\hat{P}_{12}^{N}} + \frac{1}{\hat{P}_{21}^{N}} + \frac{1}{\hat{P}_{22}^{N}} \right]$$
(6)

where  $\hat{P}_{11}^A, \hat{P}_{12}^A, \hat{P}_{21}^A, \hat{P}_{22}^A$  and  $\hat{P}_{11}^N, \hat{P}_{12}^N, \hat{P}_{21}^N, \hat{P}_{22}^N$  are the estimators of the corresponding haplotype frequencies in cases and controls, respectively. When sample sizes are large enough to ensure application of large sample theory,  $T_{IH}$  is asymptotically distributed as a central  $\chi^2_{(1)}$  distribution under the null hypothesis of no interaction between two loci. Under an alternative hypothesis of of interaction between two loci being present, the statistic  $T_{IH}$  is asymptotically distributed as a noncentral  $\chi^2_{(1)}$ distribution with noncentrality parameter proportional to the haplotype multiplicative odds-ratio interaction measure. This statistic can be applied to both linked and unlinked loci. As we explained in Text S1, Appendix B, the proposed statistic  $T_{IH}$  is different from the "fast-epistasis" test in PLINK.

For the unlinked loci, we can use case only design [27,28] to study interaction between two loci in which equation is reduced to

$$T_{IH} = \frac{\left(\log \frac{P_{11}^A P_{22}^A}{P_{12}^A P_{21}^A}\right)^2}{\frac{1}{2n_A} \left[\frac{1}{\hat{P}_{11}^A} + \frac{1}{\hat{P}_{12}^A} + \frac{1}{\hat{P}_{21}^A} + \frac{1}{\hat{P}_{22}^A}\right]}$$
(7)

# Results

# **Null Distribution of Test Statistics**

In the previous sections, we have shown that when the sample size is large enough to apply large sample theory, the distribution of the statistic  $T_{IH}$  for testing the interaction between two loci under the null hypothesis of no interaction between them is asymptotically a central  $\chi^2_{(1)}$  distribution. To examine the validity of this statement, we performed a series of simulation studies. MATLAB was used to generate two-locus genotype data of the sample individuals. A total of 100,000 individuals from a general population with an allele frequency  $P(G_1) = 0.4$ ,  $P(H_1) = 0.3$ , haplotype frequency  $P(G_1H_1) = 0.1$  and disequilibrium coefficient  $\delta = P(G_1H_1) - P(G_1)P(H_1) = -0.02$  were generated. A total of 10,000 simulations were repeated. Type I error rates were calculated by random sampling 500-1,000 individuals as cases and controls from the general population. Table 1 and Table 2 show that the estimated type I error rates of the statistic  $T_{IH}$  for testing interaction between two loci, assuming  $OR_G = OR_H = 1$ and  $OR_G = OR_H = 2$ , were not appreciably different from the nominal levels  $\alpha = 0.05$ ,  $\alpha = 0.01$  and  $\alpha = 0.001$ . To further examine the validity of the test statistic, we constructed Quantile-quantile (Q-Q) plots of the test statistic in datasets 1 and 2 shown in Figures 1A and 1B, where the P-values of the tests were plotted (as  $-\log 10$  values) as a function of p values from the expected null distribution. Since the total number of all possible pair-wise tests for interaction between SNPs is too large to store all the results in computer we only stored P-values  $<1.00\times10^{-4}$ .

**Table 1.** Type I error rates of the statistic  $T_{IH}$  to test for interaction between two loci, assuming  $OR_G = OR_H = 1$ .

Sample Size	Nominal levels								
	$\alpha = 0.05$	$\alpha = 0.01$	$\alpha = 0.001$						
300	0.04790	0.00995	0.00080						
400	0.04815	0.00820	0.00080						
500	0.04745	0.00930	0.00085						
600	0.04880	0.00850	0.00095						
700	0.05060	0.00920	0.00075						
800	0.05120	0.01015	0.00100						
900	0.04935	0.00805	0.00090						
1000	0.04860	0.00880	0.00090						

Consequently, Q-Q plots started with 4. Figures 1A and 1B showed good agreement with the null distribution.

#### **Power Evaluation**

To evaluate the performance of the statistic  $T_{IH}$  for detection of interaction between two loci, we compared the power of the statistic  $T_{IH}$  to that of the logistic model and the "fast epistasis" test in PLINK. Power was calculated by simulation. A total of 1,000,000 individuals from a general population with allele frequencies  $P(G_1)=0.2$ ,  $P(H_1)=0.3$  and  $P(G_1H_1)=0.1$  and disequilibrium coefficient  $\delta\!=\!P(G_1H_1)\!-\!P(G_1)P(H_1)\!=\!0.04$  were generated. Two-locus disease models were used to generate cases and controls, and summarized in Table 3 where odds-ratio was defined in terms of genotypes. We considered three types of genotype coding. For a recessive model, homozygous wild type, heterozygous, and homozygous risk increasing genotypes were coded as 0, 0, 1, respectively. For a dominant model, homozygous wild type, heterozygous, and homozygous risk increasing genotypes were coded as 0, 1, and 1, respectively. For an additive model, they were coded as 0, 1, and 2, respectively. The genotype coding for the logistic regression matched the simulation model. The statistic  $T_{IH}$  in equation (6) for the case-control version was used to evaluate the power. In the power simulations, we also assumed that  $OR_G = 1$  and  $OR_H = 1$ . An individual who is randomly sampled from the general population was assigned to

**Table 2.** Type I error rates of the statistic  $T_{IH}$  to test for interaction between two loci, assuming  $OR_G = OR_H = 2$ .

Sample Size	Nominal levels								
	$\alpha = 0.05$	$\alpha = 0.01$	$\alpha = 0.001$						
300	0.04990	0.00945	0.00120						
400	0.04995	0.01030	0.00085						
500	0.05170	0.01065	0.00080						
600	0.05070	0.00980	0.00100						
700	0.04725	0.00965	0.00113						
800	0.04945	0.00895	0.00075						
900	0.04830	0.00950	0.00080						
1000	0.04920	0.00975	0.00110						

doi:10.1371/journal.pgen.1001131.t002

case or control status depending on the two-locus disease models in Table 3. The process was repeated until a sample of 1,000 cases and 1,000 controls for the dominant and additive models, or a sample of 2,000 cases and 2,000 controls for the recessive model was obtained. A total of 10,000 simulations were repeated. In Figures 2A–2C, power comparisons among the logistic regression model, the "fast-epistasis" in PLINK and the statistic  $T_{IH}$  under two-locus recessive × recessive disease model for significance levels  $\alpha = 0.05$ ,  $\alpha = 0.01$  and  $\alpha = 0.001$ , respectively are presented. In Figures 3A-3C, power comparisons among the logistic regression model, the "fast-epistasis" in PLINK and the statistic  $T_{IH}$  under two-locus dominant x dominant disease model for significance levels  $\alpha = 0.05$ ,  $\alpha = 0.01$  and  $\alpha = 0.001$ , respectively are shown. In Figures 4A–4C, power comparisons between the logistic regression model and the statistic  $T_{IH}$  under two-locus additive  $\times$  additive disease model for significance levels  $\alpha = 0.05$ ,  $\alpha = 0.01$  and  $\alpha = 0.001$ , respectively are demonstrated. Several remarkable features emerge from these Figures. First, these power Figures indeed demonstrate that the power increases as the measure of the interaction between two loci increases. The power curves were plotted as a function of the traditional genotype odds ratio  $OR_{GH}$ . We observed that the power curves were a monotonic increasing function of the genotype odds ratio  $OR_{GH}$ . Therefore, the test statistic  $T_{IH}$  can detect the strength of the interaction between two loci. Second, the test statistic  $T_{IH}$  had much higher power to detect interaction between two loci than the logistic regression and the "fast-epistasis" test in PLINK. Third, the more complex the disease models were, the larger the differences in power between the test statistic  $T_{IH}$ , the "fast-epistasis" test in PLINK and logistic regression that were observed.

When two loci are unlinked where we do not observe the allelic association between two loci in the population as a whole, our results also hold. We assumed the following allele and haplotype frequencies in the population:  $P(G_1) = 0.2$ ,  $P(H_1) = 0.3$  and  $P(G_1H_1) = 0.06$ . Other parameters were defined as before. A total of 10,000 simulations were repeated to simulate the power of three statistics under three disease models with the significance level  $\alpha = 0.001$ . Figures 5A, 5B and 5C showed the power of three statistics for testing interaction between two unlinked loci under two-locus recessive × recessive, dominant × dominant, and additive × additive disease models, respectively. These Figures again demonstrated that the power of the test statistic  $T_{IH}$  was still much higher than that of the logistic regression and the "fast-epistasis" test in PLINK. The conclusions still hold for the significance levels  $\alpha = 0.05$  and  $\alpha = 0.01$  (Data were not shown).

# Application to Pathway-Based Genome-Wide Interaction **Analysis of Psoriasis**

To evaluate its performance for detection of interaction between two loci, the proposed test statistic  $T_{IH}$  was applied to interaction analysis of two independent GWAS datasets of psoriasis which were downloaded from dbGaP. Psoriasis is a common chronic inflammatory skin disease affecting 2%-3% of the world population. Originally, the first study included 955 individuals with psoriasis and 693 controls, which is considered as dataset 1. The second replication study included 466 individuals with psoriasis and 732 controls, which is designated dataset 2. All cases and controls are of European origin [29–31]. After using PLINK [20] to check for contamination, cryptic family relationship and non-Caucasian ancestry, 123 samples were excluded. Subsequently we retained for analysis 915 cases and 675 controls from the first study and 431 cases and 702 controls from the second study. All 2,723 samples had been genotyped with the Perlegen 500K array. In the initial dataset, 451,724 SNPs passed quality control (call




Figure 1. Quantile-quantile plots for the test statistic  $T_{IH}$ . (A) Quantile-quantile plots for the test statistic  $T_{IH}$  in dataset 1. The P-values ( $<1.0 \times 10^{-4}$ ) for the test are plotted (as  $-\log 10$  values) as a function of its expected p values. (B) Quantile-quantile plots for the test statistic  $T_{IH}$  in dataset 2. The P-values ( $<1.0 \times 10^{-4}$ ) for the test are plotted (as  $-\log 10$  values) as a function of its expected p values. doi:10.1371/journal.pgen.1001131.g001

Table 3. Two-locus disease models.

Recessive × Recessive								
Locus 1\2	$D_2D_2$	D <sub>2</sub> d <sub>2</sub>	d <sub>2</sub> d <sub>2</sub>					
$D_1D_1$	$\frac{e^{\alpha}OR_{G}OR_{H}OR_{GH}}{1 + e^{\alpha}OR_{G}OR_{H}OR_{GH}}$	$\frac{e^{\alpha}OR_G}{1+e^{\alpha}OR_G}$	$\frac{e^{\alpha}OR_G}{1+e^{\alpha}OR_G}$					
$D_1d_1$	$\frac{e^{\alpha}OR_{H}}{1+e^{\alpha}OR_{H}}$	$\frac{e^{\alpha}}{1+e^{\alpha}}$	$\frac{e^{\alpha}}{1+e^{\alpha}}$					
$d_1d_1$	$\frac{e^{\alpha}OR_{H}}{1+e^{\alpha}OR_{H}}$	$\frac{e^{\alpha}}{1+e^{\alpha}}$	$\frac{e^{\alpha}}{1+e^{\alpha}}$					

Dominant ×	Dominant		
Locus 1\2	$D_2D_2$	$D_2d_2$	d <sub>2</sub> d <sub>2</sub>
$D_1D_1$	$\frac{e^{\alpha}OR_{G}OR_{H}OR_{GH}}{1+e^{\alpha}OR_{G}OR_{H}OR_{GH}}$	$\frac{e^{\alpha}OR_{G}OR_{H}OR_{GH}}{1+e^{\alpha}OR_{G}OR_{H}OR_{GH}}$	$\frac{e^{\alpha}OR_G}{1+e^{\alpha}OR_G}$
$D_1d_1$	$\frac{e^{\alpha}OR_{G}OR_{H}OR_{GH}}{1 + e^{\alpha}OR_{G}OR_{H}OR_{GH}}$	$\frac{e^{\alpha}OR_{G}OR_{H}OR_{GH}}{1+e^{\alpha}OR_{G}OR_{H}OR_{GH}}$	$\frac{e^{\alpha}OR_G}{1+e^{\alpha}OR_G}$
$d_1d_1$	$\frac{e^{\alpha}OR_{H}}{1+e^{\alpha}OR_{H}}$	$\frac{e^{\alpha}OR_{H}}{1+e^{\alpha}OR_{H}}$	$\frac{e^{\alpha}}{1+e^{\alpha}}$

#### Additive × Additive

Locus 1\2	$D_2D_2$	$D_2d_2$	d <sub>2</sub> d <sub>2</sub>
$D_1D_1$	$\frac{e^{\alpha} O R_{G}^{2} O R_{H}^{2} O R_{GH}^{4}}{1 + e^{\alpha} O R_{G}^{2} O R_{H}^{2} O R_{GH}^{4}}$	$\frac{e^{\alpha}OR_{G}^{2}OR_{H}OR_{GH}^{2}}{1+e^{\alpha}OR_{G}^{2}OR_{H}OR_{GH}^{2}}$	$\frac{e^{\alpha}OR_{G}^{2}}{1+e^{\alpha}OR_{G}^{2}}$
$D_1d_1$	$\frac{e^{\alpha}OR_GOR_H^2OR_{GH}^2}{1 + e^{\alpha}OR_GOR_H^2OR_{GH}^2}$	$\frac{e^{\alpha}OR_{G}OR_{H}OR_{GH}}{1 + e^{\alpha}OR_{G}OR_{H}OR_{GH}}$	$\frac{e^{\alpha}OR_G}{1+e^{\alpha}OR_G}$
$d_1d_1$	$\frac{e^{\alpha}OR_{H}^{2}}{1+e^{\alpha}OR_{H}^{2}}$	$\frac{e^{\alpha}OR_{H}}{1+e^{\alpha}OR_{H}}$	$\frac{e^{\alpha}}{1+e^{\alpha}}$

 $e^{\alpha}=rac{p_0}{1-p_0}$ ,  $p_0$  is the prevalence of the disease in the population. The elements in the Table are the penetrance as a function of the joint genotype at loci 1 and 2 with rows indexing genotype at locus 1 and columns indexing genotype at locus 2. doi:10.1371/journal.pgen.1001131.t003

rate>95%). To further ensure the quality of the typed SNPs, we used PLINK software to remove the SNPs with >5% missing genotypes, Hardy-Weinberg disequilibrium (P-values <0.0001), MAF<0.01 and duplicated markers. In this application, we only considered common SNPs with MAF>0.01. After quality control filtering, a total of 451,724 SNPs were pruned to 443,018 and 439,201 SNPs with the average genotyping rate 99.3% in the first and second studies, respectively.

Since testing for all possible two-locus interactions across the genome in genome-wide interaction analysis requires extremely large computation, we conducted pathway-based genome-wide interaction analysis. We assembled 501 pathways from KEGG [24] and Biocarta (http://www.biocarta.com). The assignment of SNPs to a gene was obtained from NCBI human9606 database (version b129). We used the statistic  $T_{IH}$  to test interactions of all possible pairs of SNPs located in genes within the assembled 501 pathways. The total number of SNPs in dataset 1 and dataset 2 being tested was 50,327 and 49,876, respectively. The serious problem in genome-wide interaction analysis is multiple testing. We used two strategies to tackle this problem. One is to use false discovery rate (FDR) [32] to declare significance of interaction. Another is replication of the findings in two independent studies, which enhances confidence in interaction tests [22]. We looked for consistent results across the two independent studies.

In total, 44 pairs of SNPs showed significant evidence of interactions with FDR < 0.001, which roughly corresponds to the P-value <  $1.0 \times 10^{-7}$ , in two independent studies (Table S1). These 44 pairs of SNPs were derived from 71 distinct SNPs located in 60 genes, including HLA-C, HLA-DRA, HLA-DPA1, LST1, MICB and NOTCH4. Of 44 pairs of SNPs, only one pair of interacting SNPs: rs2395471 and rs2853950 showed significant marginal association in two independent studies. An additional 211 pairs of SNPs with FDR less than 0.003 in the two studies is listed in Table S2. These interacting SNPs were mainly located in 19 pathways, including a number of signaling pathways, and immune-related antigen processing and presentation as well as natural killer cell mediated cytotoxicity pathways (Figure 6). Several remarkable features emerge from these results. First, although we can observe a few interactions between SNPs within a gene, the majority of




Figure 2. Power of the statistics for testing interaction between two linked loci under recessive disease model. (A) The power of the test statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression analysis for testing interaction between two linked loci as a function of traditional odds-ratio  $OR_{GH}$  under a two-locus recessive × recessive disease model, where the number of individuals in both the case and control groups is 2,000, the significance level is 0.05, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ . (B) The power of the test statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression analysis for testing interaction between two linked loci as a function of traditional odds-ratio  $OR_{GH}$  under a two-locus recessive × recessive disease model, where the number of individuals in both the case and control groups is 2,000, the significance level is 0.01, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ . (C) The power of the test statistic  $OR_{GH}$  under a two-locus recessive × recessive disease model, where the number of individuals in both the case and control groups is 2,000, the significance level is 0.001, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ . (doi:10.1371/journal.pgen.1001131.g002

interactions occurred between genes that are often in different pathways. Since the number of SNPs typed within each gene was limited, it is unknown whether this is a general rule or just a special case. Second, a SNP in one gene might interact with multiple SNPs in multiple genes. For example, SNP rs3131636 in the gene MICB interacting with the SNPs rs915895, rs443198, rs3134929 in the gene NOTCH4, the SNP rs1052248 in the gene LAST1/Natural cytotoxicity triggering receptor 3 (NCR3) and the SNP rs1799964 in the gene LTA/TNF. SNP rs1799964 in the gene LTA/TNF interacting with SNPs rs3131636, rs3132468 in the

gene MICB, SNPs rs9268658 and rs3135392 in the gene HLA-DRA, SNP rs2227956 in the gene HSPA1L. However, this does not imply that multiple causal SNPs within a gene will interact with multiple causal SNPs within another gene. It is quite likely that this is due to LD between the SNPs within a gene. Third, although interacting SNPs did not form large connected networks, the interacting SNPs connected pathways into a large complicated network. This may imply that many genes and pathways are involved in the development of psoriasis. Fourth, upstream of many pathways included genes with interacting SNPs. For example,




Figure 3. Power of the statistics for testing interaction between two linked loci under dominant disease model. (A) The power of the test statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression analysis for testing interaction between two linked loci as a function of traditional odds-ratio  $OR_{GH}$  under a two-locus dominant × dominant disease model, where the number of individuals in both the case and control groups is 1,000, the significance level is 0.05, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ . (B) The power of the test statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression analysis for testing interaction between two linked loci as a function of traditional odds-ratio  $OR_{GH}$  under a two-locus dominant × dominant disease model, where the number of individuals in both the case and control groups is 1,000, the significance level is 0.01, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ . (C) The power of the test statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression analysis for testing interaction between two linked loci as a function of traditional odds-ratio  $OR_{GH}$  under a two-locus dominant × dominant disease model, where the number of individuals in both the case and control groups is 1,000, the significance level is 0.001, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ .

doi:10.1371/journal.pgen.1001131.g003




Figure 4. Power of the statistics for testing interaction between two linked loci under additive disease model. (A) The power of the test statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression for testing interaction between two linked loci analysis as a function of traditional odds-ratio  $OR_{GH}$  under a two-locus additive × additive disease model, where the number of individuals in both the case and control groups is 1,000, the significance level is 0.05, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ . (B) The power of the test statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression for testing interaction between two linked loci analysis as a function of traditional odds-ratio  $OR_{GH}$  under a two-locus additive × additive disease model, where the number of individuals in both the case and control groups is 1,000, the significance level is 0.01, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ . (C) The power of the test statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression for testing interaction between two linked loci analysis as a function of traditional odds-ratio  $OR_{GH}$  under a two-locus additive × additive disease model, where the number of individuals in both the case and control groups is 1,000, the significance level is 0.001, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ . doi:10.1371/journal.pgen.1001131.q004

genes MICB, CHRM3, HLA-DRA and CIITA, EPHB1 and EPHB2, LAMA1 and LANA5, ITGA1, LTBP1, TNF, and FGF20 that contain interacting SNPs are in the upstream of natural killer cell mediated cytotoxicity, calcium signaling pathway, antigen processing and presentation, axon guidance, ECM-receptor interaction pathway, focal adhesion, TGFB pathway, MAPK pathway and regulation of acting cytoskeleton, respectively. Fifth, most interacting SNPs are in introns and accounted for 77% of total interacting SNPs.

Table 4 listed 15 pairs of interacting SNPs that have non-synonymous substitutions. It is unknown how these nonsynon-

ymous mutations are involved in the pathogenesis of psoriasis. From the literature we know that Plexin C1 receptor is a tumor suppressor gene for melanoma [33], NOTCH4 is involved in schizophrenia [34], Phosphodiesterase 4D (PDE4D) is associated with ischemic stroke [35], HLA-DRA is one of the HLA class II alpha chain genes that plays a central role in antigen processing, and neuregulin 1 (NRG1) has been implicated in diseases such as cancer, schizophrenia and bipolar disorder [36].

Table 5 includes five interacting pairs of SNPs, one of which falls in the microRNA (MiRNA) binding region. miRNAs, which are 22 nucleotide small RNAs and regulate gene expressions by





Figure 5. Power of the statistics for testing interaction between two unlinked loci. (A) The power of the test statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression analysis for testing interaction between two unlinked loci as a function of traditional odds-ratio  $OR_{GH}$  under a two-locus recessive × recessive disease model, where the number of individuals in both the case and control groups is 2,000, the significance level is 0.001, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ . (B) The power of the test statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression analysis for testing interaction between two unlinked loci as a function of traditional odds-ratio  $OR_{GH}$  under a two-locus dominant × dominant disease model, where the number of individuals in both the case and control groups is 1,000, the significance level is 0.001, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ . (C) The power of the test statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression analysis for testing interaction between two unlinked loci as a function of traditional odds-ratio  $OR_{GH}$  under a two-locus additive × additive disease model, where the number of individuals in both the case and control groups is 1,000, the significance level is 0.001, and the odds-ratios at two loci were  $OR_G = OR_H = 1$ .

doi:10.1371/journal.pgen.1001131.g005



**Figure 6. Interacting SNPs that were located in 19 pathways formed a network.** Each pathway was represented by an ellipse with the number. The SNPs were represented by nodes and placed insight their located pathways. Nearby each SNP there was its RS number and the name of its located gene. The pathway and its harbored SNPs were labeled by the same color. The interacting SNPs were connected by the solid light green lines.

pairing the miRNA seed region with the target sites, have been implicated in many biological processes including the immune response, biogenesis and tumorigenesis [37]. Mutations in the target sites will affect miRNA activity. A number of studies have identified polymorphisms in the miRNA target sites associated with the diseases [37]. Interestingly, we identified four SNPs in the miRNA (miR-324-3p, miR-433, and miR-382) target sites which interact with five SNPs to contribute to psoriasis. In previous studies, miR-382 has been associated with dermatomyositis, Duchenne muscular dystrophy and Miyoshi myopathy [38], miR-433 and miR-324 with lupus nephritis [39] and miR-433 with Parkinson's disease [40].

Some researchers suggest that in genome-wide interaction analysis only SNPs with large or mild marginal genetic effects should be tested for interaction. To examine whether this strategy will miss detection of interacting SNPs, we showed in Table 6 the 20 top pairs of interacting SNPs and in Table S3 all pairs of interacting SNPs with FDR less than 0.003. Surprisingly, 75% of SNPs with P-values (in dataset 1) larger than 0.2 and 44% of SNPs with P-values larger than 0.5 in two studies were observed in Table S3. Table 6 and Table S3 strongly demonstrated that while both SNPs did not demonstrate significant evidence of marginal association, they did show significant evidence of interaction.

To further evaluate the performance of the proposed statistic  $T_{IH}$ , in Table 7 and Table S4 we list P-values for testing interaction calculated by the statistic  $T_{IH}$ , the "fast-epistasis" in PLINK and logistic regression using genotype coding. In Table 7 the 20 top pairs of interacting SNPs and in Table S4 the results of 233 pairs of interacting SNPs are presented. The P-values for interaction calculated by the statistic  $T_{IH}$  are much smaller than those from the "fast-epistasis" in PLINK and the logistic regression using genotype coding (Table 7 and Table S4). Moreover, the "fast-epistasis" in PLINK and the logistic regression coded by genotype detect very few interactions that can be replicated in two independent studies (Table 7 and Table S4). In fact, our results for all tested SNPs in 501 pathways showed that the "fast-epistasis" in PLINK and logistic regression coded by genotypes detected very few interactions that can be replicated in two studies (data not shown).

Eighteen significantly interacting SNPs identified by Bonferroni correction were listed in Table 8. In dataset1, the total number of SNPs for testing interaction was 50,327. The P-values for declaring interaction between SNPs after Bonferroni correction was  $3.95 \times 10^{-11}$ . We found that there were 2,210 significant interactions with P-values less than  $3.51 \times 10^{-11}$  in the dataset 1. Then, interaction for all these 2,210 pairs of SNPs in the dataset 2

Table 4. Interacting SNPs with non-synonymous mutation.

SNP1(rs)	Gene1	SNP2(rs)	Gene2	Dataset 1		Dataset 2		Nonsynonymous mutation	Protein Residue
				P-Value	FDR	P-Value	FDR	_	
10837771	OR51B4	16973321	RYR3	1.20E-07	9.00E-04	2.28E-07	1.34E-03	rs10837771	Т
7671095	GRID2	10839659	OR2D3	2.00E-08	3.97E-04	2.82E-08	5.29E-04	rs10839659	S
1545133	POLR1B	8064077	MYH11	6.71E-07	1.97E-03	5.88E-07	2.06E-03	rs1545133	L
1958715	OR4L1	3844750	EFNA5	2.15E-08	4.10E-04	1.25E-07	1.03E-03	rs1958715	N
1958716	OR4L1	3844750	EFNA5	4.48E-08	5.73E-04	1.22E-07	1.02E-03	rs1958716	V
2227956	HSPA1L	3135392	HLA-DRA	3.20E-10	6.02E-05	7.82E-10	1.05E-04	rs2227956	М
2227956	HSPA1L	3134929	NOTCH4	7.76E-09	2.57E-04	2.36E-11	2.07E-05	rs2227956	М
1799964	LTA/TNF	2227956	HSPA1L	7.52E-09	2.53E-04	2.98E-08	5.42E-04	rs2227956	М
1052248	LST1/NCR3	2227956	HSPA1L	8.24E-07	2.17E-03	1.87E-08	4.40E-04	rs2227956	М
35258	PDE4D	2230793	IKBKAP	7.50E-08	7.24E-04	7.85E-07	2.34E-03	rs2230793	L
2254524	LSS	10860869	IGF1	8.58E-08	7.70E-04	6.35E-09	2.71E-04	rs2254524	V
327325	NRG1	3742290	UTP14C	7.47E-07	2.07E-03	5.90E-07	2.06E-03	rs3742290	Α
4253211	ERCC6	10435892	GABBR2	5.60E-07	1.81E-03	1.11E-09	1.23E-04	rs4253211	Р
940389	STON1	10745676	PLXNC1	2.20E-08	4.14E-04	7.02E-07	2.23E-03	rs940389	Т
676925	CXCR5	999890	PIP5K3	3.07E-07	1.38E-03	2.93E-07	1.51E-03	rs999890	Α

was examined. The P-values for declaring interaction between SNPs after Bonferroni correction in dataset 2 was  $2.26 \times 10^{-5}$ . We identified eight significant interactions that were replicated in dataset 2. Similarly, if we started with dataset 2, the total number of SNPs for testing interaction was 49,876. The P-values for declaring interaction between SNPs after Bonferroni correction was  $4.02 \times 10^{-11}$ . Significant interactions with the P-values less than  $3.87 \times 10^{-11}$  in dataset 2 were seen between 1,913 pairs of SNPs. Then, we tested for interaction for all these 1,913 pairs of SNPs in the dataset 1. The P-values for declaring interaction between SNPs after Bonferroni correction in dataset 1 was  $2.61 \times 10^{-5}$ , and 10 significant interactions were detected that were replicated in the dataset 1. A total of 9 interactions were common in Table 8 and Table S1 and Table S2.

#### Discussion

The development of most diseases is a dynamic process of genegene and gene-environment interactions within a complex biological system. We expect that genome-wide interaction analysis will provide a possible source of finding missing heritability unexplained by current GWAS that test association individually. But, in practice, very few genome-wide interaction analyses have been conducted and few significant interaction results have been reported. Our aim is to develop statistical methods and computational algorithms for genome-wide interaction analysis which can be implemented in practice and provide evidence of gene-gene interaction. The purpose of this report is to address several issues to achieve this goal.

The first issue is how to define and measure interaction. Oddsratio is a widely used measure of interaction for case-control design. The odds-ratio based measure of interaction between two loci is often defined as a departure from additive or multiplicative odds-ratios of both loci defined by genotypes. The genotype-based odds-ratio does not explore allelic association information between two loci generated by interaction between them in the cases. Any statistics that are based on genotype defined odds-ratio will often have low power to detect interaction. To overcome this limitation, we extended genotype definition of odds-ratio to haplotypes and revealed relationships between haplotype-defined odds-ratio and haplotype formulation of logistic regression. To further examine the validity of this concept, we studied the distribution of the test statistic under the null hypothesis of no interaction between two either linked or unlinked loci. Through extensive simulation

**Table 5.** Five pairs of interacting SNPs, one of which falls in the microRNA binding region.

SNP1(rs)	Gene 1	SNP2(rs)	Gene 2	Dataset 1 Dataset 2		Dataset 1 Dataset 2				MicroRNA Binding Site
				P-Value	FDR	P-Value	FDR			
1052248	LST1/NCR3	2227956	HSPA1L	8.24E-07	2.17E-03	1.87E-08	4.40E-04	rs1052248 (miR-324-3p)		
1052248	LST1/NCR3	3131636	MICB	5.56E-13	3.03E-06	7.76E-10	1.04E-04	rs1052248 (miR-324-3p)		
676925	CXCR5/BCL9L	999890	PIP5K3	3.07E-07	1.38E-03	2.93E-07	1.51E-03	rs676925 (miR-382)		
163274	ACSM1	2638315	GLS2	8.16E-07	2.16E-03	9.14E-07	2.51E-03	rs2638315 (miR-433)		
2072619	MYH11	3822711	GALNT10	1.83E-07	1.09E-03	3.77E-08	6.03E-04	rs3822711 (miR-324-3p)		

doi:10.1371/journal.pgen.1001131.t005



Table 6. Top 20 pairs of interacting SNPs.

	Associatio	n of SNP			Association of SNP								
	P-value				P-value			Dataset 1		Dataset 2			
SNP1(rs)	Dataset 1	Dataset 2	Gene 1	SNP2(rs)	Dataset 1	Dataset 2	Gene 2	P-Value	FDR	P-Value	FDR		
626072	0.227074	0.053394	LAMA1	6121989	0.862496	0.311346	LAMA5	1.11E-15	1.41E-07	5.67E-07	2.03E-03		
626072	0.227074	0.053394	LAMA1	4925386	0.935809	0.264641	LAMA5	1.47E-13	1.73E-06	9.81E-07	2.59E-03		
1052248	1.28E-05	0.002907	LST1/NCR3	3131636	0.012961	0.0006472	MICB	5.56E-13	3.03E-06	7.76E-10	1.04E-04		
1052248	1.28E-05	0.002907	LST1/NCR3	3132468	0.014008	0.0005969	MICB	8.41E-13	3.70E-06	8.96E-10	1.12E-04		
443198	0.000703	2.35E-11	NOTCH4	3131636	0.012961	0.0006472	MICB	1.13E-11	1.24E-05	3.98E-08	6.18E-04		
443198	0.000703	2.35E-11	NOTCH4	3132468	0.014008	0.0005969	MICB	1.19E-10	3.76E-05	6.55E-08	7.72E-04		
1799964	0.001104	0.009606	LTA/TNF	3131636	0.012961	0.0006472	MICB	1.62E-10	4.35E-05	1.36E-09	1.34E-0		
1799964	0.001104	0.009606	LTA/TNF	3132468	0.014008	0.0005969	MICB	2.94E-10	5.80E-05	2.51E-09	1.78E-04		
4766587	0.813376	0.391864	ACACB	4807055	0.530091	0.0742653	NDUFA11	3.07E-10	5.90E-05	6.61E-07	2.17E-0		
2227956	0.001216	0.000149	HSPA1L	3135392	0.581239	0.75373	HLA-DRA	3.20E-10	6.02E-05	7.82E-10	1.05E-04		
1060856	0.824965	0.751351	ALDH7A1	2711288	0.258241	0.0910624	PRKCE	3.57E-10	6.33E-05	2.56E-07	1.42E-03		
326346	0.979881	0.212752	CD47	11081513	0.229512	0.79174	VAPA	4.24E-10	6.84E-05	2.81E-07	1.48E-03		
1932067	0.043627	0.970441	PAFAH2	13203100	0.208767	0.598145	TIAM2	5.64E-10	7.81E-05	3.04E-08	5.47E-04		
2012359	0.369854	0.40799	PARP4	10823333	0.614239	0.882698	HK1	5.65E-10	7.82E-05	7.20E-07	2.25E-03		
9311951	0.131357	0.719726	MAGI1	11195879	0.361463	0.072601	NRG3	8.53E-10	9.50E-05	8.25E-07	2.40E-03		
3768650	0.318227	0.611621	STAM2	11993811	0.732675	0.862927	FGF20	9.20E-10	9.81E-05	3.25E-08	5.64E-04		
785915	0.290127	0.406203	GCNT1	11713331	0.752161	0.621571	PRICKLE2	1.30E-09	1.15E-04	2.95E-07	1.51E-03		
785916	0.274961	0.307539	GCNT1	11713331	0.752161	0.621571	PRICKLE2	1.37E-09	1.17E-04	5.51E-07	2.00E-03		
1202674	0.254783	0.978976	RPS6KA2	6061796	0.952187	0.932697	CDH4	2.46E-09	1.52E-04	1.63E-08	4.14E-04		
1048471	0.414631	0.566854	ST3GAL1	2830096	0.754145	0.728396	APP	2.95E-09	1.65E-04	9.63E-07	2.57E-03		

(assuming allelic association in the controls), we show that the distribution of the haplotype odds-ratio-based statistic is close to a central  $\chi^2_{(1)}$  distribution even for small sample size and that type I error rates were close to the nominal significance levels.

The second issue is the power of the test statistic for genome-wide interaction analysis. The genome-wide interaction analysis requires testing billions of pairs of SNPs for interactions. The P-values for ensuring genome-wide significance level should be very small. Therefore, developing statistics with high power to detect interaction is an essential issue for the success of genome-wide interaction analysis. As an alternative to the logistic regression and the "fast-epistasis" in PLINK, we presented a haplotype odds-ratio-based statistic for detection of interaction between two loci and illustrated its power by extensive simulations. The power of the haplotype odds-ratio-based statistic ended up being a function of the measure of interaction and had much higher power to detect interaction than the "fast-epistasis" in PLINK and logistic regression.

The third issue is whether the interactions exist with no marginal association and how often they might occur in practice. Our data demonstrated that the majority of the significantly interacting SNPs showed no marginal association. Surprisingly, 75% of interacting SNPs with P-values (for testing marginal association) larger than 0.2 and 44% of interacting SNPs with P-values (for testing marginal association) larger than 0.5 in two studies were observed in our analysis. This strongly suggested that testing interaction for only SNPs with strong or mild marginal association will miss the majority of interactions.

The fourth issue is that of replication of the results. Genomewide interaction analysis involves testing billions of pairs of SNPs. Even if after correction of multiple tests, the false positive results might be still high. To increase confidence in interaction test results, replication of interaction findings in independent studies is often sought. To date, very few results of genome-wide interaction analysis have been replicated. This begs the question whether the significant interaction can be replicated in independent studies. In this report, we show that interaction findings can be replicated in two independent studies.

The fifth issue is correction for multiple testing. Genome-wide interaction analysis often involves billions of tests, which would require an extremely small Bonferroni-corrected P-value to ensure a genome-wide significance level of 0.05. Replication of finding at such small P-values in independent studies is often extremely difficult. However, Bonferroni correction assumes that the tests are independent, yet many interaction tests are highly correlated. Correlations in the interaction tests come from two levels [23]. First, two pairs of SNPs may share a common SNP. Second, SNPs in the interaction tests may be dependent due to allelic association. The Bonferroni correction assuming independent tests will be overly conservative due to high correlations among the interaction tests. In this report, two strategies were used to tackle the multiple testing issues. The first is to use FDR to control type I error. The second is to replicate interaction finding. Replication allows us to detect the interactions that are frequent and consistent [22]. This approach still has the limitation that we still make independent assumption of the tests in calculation of FDR. Recently, Emily et al. (2009) [23] proposed to develop a Bonferroni-like correction for multiple tests based on the concept of the effective number of SNP pairs. The concept of the effective number of tests takes correlation among the tests into account and can be applied to both P-value

**Table 7.** P-values of 20 pairs of interacting SNPs calculated by the statistic TIH, PLINK, and logistic regression coded by genotypes.

				P-Value										
				Dataset1					Dataset	2				
				T <sub>IH</sub>	PLINK	Logistic Re	gression		T <sub>IH</sub>	PLINK	Logistic Regression			
rs1	Gene 1	rs2	Gene 2	Gene 2			Recessive	Additive	Dominan	t		Recessive	Additive	Dominant
626072	LAMA1	6121989	LAMA5	1.11E-15	1.63E-07	2.61E-02	7.82E-08	3.14E-06	5.67E-07	0.001854	3.65E-02	1.40E-03	1.10E-01	
626072	LAMA1	4925386	LAMA5	1.47E-13	1.01E-06	7.64E-02	5.82E-07	1.05E-05	9.81E-07	0.002709	5.07E-02	1.88E-03	1.27E-01	
1052248	LST1/NCR3	3131636	MICB	5.56E-13	2.86E-09	8.61E-03	1.14E-09	1.11E-05	7.76E-10	1.76E-05	4.47E-01	9.67E-06	9.75E-06	
1052248	LST1/NCR3	3132468	MICB	8.41E-13	4.28E-09	1.16E-02	1.72E-09	1.10E-05	8.96E-10	2.03E-05	4.75E-01	9.97E-06	7.73E-06	
443198	NOTCH4	3131636	MICB	1.13E-11	6.14E-08	3.29E-01	2.95E-08	4.53E-05	3.98E-08	6.33E-05	2.93E-02	3.63E-05	7.83E-04	
443198	NOTCH4	3132468	MICB	1.19E-10	2.81E-07	3.21E-01	1.52E-07	1.57E-04	6.55E-08	6.32E-05	2.81E-02	4.65E-05	1.39E-03	
1799964	LTA/TNF	3131636	MICB	1.62E-10	3.08E-07	7.09E-02	1.52E-07	3.68E-02	1.36E-09	7.26E-05	4.19E-01	3.25E-05	2.59E-06	
1799964	LTA/TNF	3132468	MICB	2.94E-10	7.26E-07	9.57E-02	3.80E-07	3.80E-02	2.51E-09	8.30E-05	4.51E-01	4.33E-05	2.76E-06	
4766587	ACACB	4807055	NDUFA11	3.07E-10	6.25E-05	3.13E-04	4.84E-05	4.51E-01	6.61E-07	0.000855	3.27E-03	7.74E-04	9.85E-01	
2227956	HSPA1L	3135392	HLA-DRA	3.20E-10	2.46E-06	1.14E-04	1.49E-06	2.63E-02	7.82E-10	9.60E-06	7.29E-05	5.17E-06	2.14E-01	
1060856	ALDH7A1	2711288	PRKCE	3.57E-10	3.01E-05	1.93E-07	1.71E-05	8.81E-01	2.56E-07	0.000292	7.50E-01	2.09E-04	2.26E-04	
2012359	PARP4	10823333	HK1	5.65E-10	3.84E-05	1.26E-04	2.70E-05	1.37E-01	7.20E-07	0.000148	2.06E-04	7.68E-05	1.00E+00	
9311951	MAGI1	11195879	NRG3	8.53E-10	6.22E-05	1.00E-03	3.29E-05	3.40E-03	8.25E-07	0.001808	3.81E-02	1.09E-03	1.71E-02	
3768650	STAM2	11993811	FGF20	9.20E-10	4.53E-06	8.71E-05	2.52E-06	1.18E-01	3.25E-08	0.000115	1.25E-03	9.91E-05	8.50E-01	
785915	GCNT1	11713331	PRICKLE2	1.30E-09	5.34E-05	5.01E-01	3.64E-05	3.37E-04	2.95E-07	3.82E-05	7.13E-05	4.26E-05	3.70E-02	
785916	GCNT1	11713331	PRICKLE2	1.37E-09	6.08E-05	5.08E-01	4.21E-05	4.32E-04	5.51E-07	6.98E-05	1.31E-04	8.08E-05	6.61E-02	
1202674	RPS6KA2	6061796	CDH4	2.46E-09	4.19E-05	3.78E-01	3.11E-05	1.12E-05	1.63E-08	0.000516	6.48E-03	3.18E-04	7.53E-04	
1048471	ST3GAL1	2830096	APP	2.95E-09	2.43E-05	4.55E-04	1.84E-05	1.00E-01	9.63E-07	0.001105	1.11E-01	1.09E-03	3.65E-03	
1025951	GALNT13	17568302	FMO2	3.40E-09	3.39E-05	3.16E-03	2.36E-05	2.26E-01	9.29E-07	0.002402	3.30E-03	1.94E-03	1.39E-02	
6954	KIAA0467	4773873	ABCC4	3.67E-09	3.30E-06	1.24E-04	2.25E-06	3.11E-03	4.74E-07	0.003416	5.42E-01	1.59E-03	1.36E-02	

**Table 8.** A total of 18 significantly interacting SNPs identified by Bonferroni Correction.

SNP1 (rs)	Gene 1	Chrom 1	Position 1	SNP2 (rs)	Gene 2	Chrom 2	Position 2	P-value	
								Dataset 1	Dataset 2
1052248	LST1/NCR3	6	31664560	3131636	MICB	6	31584073	5.56E-013	7.76E-010
1052248	LST1/NCR3	6	31664560	3132468	MICB	6	31583465	8.41E-013	8.96E-010
443198	NOTCH4	6	32298384	3131636	MICB	6	31584073	1.13E-011	3.98E-008
626072	LAMA1	18	6941189	6121989	LAMA5	20	60350108	1.11E-015	5.67E-007
626072	LAMA1	18	6941189	4925386	LAMA5	20	60354439	1.47E-013	9.81E-007
7113099	NCAM1	11	112409545	10025210	SCD5	4	83858485	2.05E-011	1.00E-005
802509	CNTNAP2	7	145603003	1462140	HPSE2	10	100355999	2.29E-011	1.96E-005
832504	PLXNC1	12	93197019	13222291	KDELR2	7	6483965	2.55E-012	2.19E-005
2227956	HSPA1L	6	31886251	3134929	NOTCH4	6	32300085	7.76E-009	2.36E-011
3129869	HLA-DRA	6	32513649	3177928	HLA-DRA	6	32520413	3.77E-008	5.65E-014
3177928	HLA-DRA	6	32520413	9269080	HLA-DRB4	6	32548947	1.96E-007	3.70E-011
3129882	HLA-DRA	6	32517508	3177928	HLA-DRA	6	32520413	6.96E-007	2.71E-014
2620452	CNTNAP2	7	146644926	16982241	FUT2	19	53894671	1.50E-006	3.48E-012
1479838	CNTNAP2	7	146638597	16982241	FUT2	19	53894671	1.85E-006	1.77E-012
3134929	NOTCH4	6	32300085	3177928	HLA-DRA	6	32520413	2.81E-006	<1.00E-17
2856993	TAP2	6	32899381	9269080	HLA-DRB4	6	32548947	8.99E-006	1.71E-013
6498575	MYH11	16	15795817	9364864	RPS6KA2	6	166984655	1.14E-005	1.83E-012
935672	PRKCE	2	45899463	2744600	ALDH5A1	6	24641411	2.09E-005	1.88E-011

doi:10.1371/journal.pgen.1001131.t008



and FDR correction [41]. This may be a promising approach to multiple test corrections in the genome-wide interaction analysis.

Although our data show that interactions can partially find the heritability of complex diseases missed by the current GWAS, they are still preliminary. Due to extremely intensive computations demanded by genome-wide interaction analysis we only tested interactions of a small set of SNPs which were located in the genes of 501 assembled pathways in a PC computer. The truly whole genome interaction analysis in which we will test for interactions between all possible pairs of SNPs across the genome has not been conducted. Gene-gene interaction is an important, though complex concept. The statistical interactions are scale dependent. There are a number of ways to define gene-gene interaction. How to define gene-gene interaction and develop efficient statistical methods and computational algorithms for genome-wide interaction analysis are still great challenges facing us. The main purpose of this report is to stimulate discussion about what are the optimal strategies for genome-wide interaction analysis. We expect that in coming years, genome-wide interaction analysis will be one of major tasks in searching for remaining heritability unexplained by the current GWAS approach.

# **Supporting Information**

**Table S1** A total of 44 pairs of SNPs showing significant interaction with FDR less than 0.001 in two independent studies. Found at: doi:10.1371/journal.pgen.1001131.s001 (0.04 MB XLS)

**Table S2** A total of 211 pairs of interacted SNPs with FDR less than 0.003 in at two studies.

## References

- Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al. (2009) Finding the missing heritability of complex diseases. Nature 461: 747–753.
- Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106: 9362–936 7.
- Frazer KA, Murray SS, Schork NJ, Topol EJ (2009) Human genetic variation and its contribution to complex traits. Nat Rev Genet 10: 241–251.
- Altshuler D, Daly MJ, Lander ES (2008) Genetic mapping in human disease. Science 322: 881–888.
- Ay N (2002) Locality of global stochastic interaction in directed acyclic networks. Neural Comput 14: 2959–2980.
- Murcary CE, Lewinger JP, Gauderman WJ (2009) Gene-environment interaction in genome-wide association studies. Am J Epidemiol 169: 219–226.
- Phillips PC (2008) Epistasis—the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet 9: 855–867.
- Cordell HJ (2009) Detecting gene-gene interactions that underlie human diseases. Nat Review Genet 10: 392–404.
- Andrieu N, Goldstein AM (1998) Epidemiologic and genetic approaches in the study of gene-environment interaction: an overview of available methods. Epidemiol Rev 20: 137–147.
- Manolio TA, Bailey-Wilson JE, Collins FS (2006) Genes, environment and the value of prospective cohort studies. Nat Rev Genet 7: 812–820.
- Ottman R (1996) Theoretic epidemiology. Gene-environment interaction: definitions and study designs. Preventive Medicine 25: 764–770.
- Moore JH, Williams SM (2005) Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. Bioassays 27: 637–646.
- Alvarez-Castro JM, Carlborg O (2007) A unified model for functional and statistical epistasis and its application in quantitative trait loci analysis. Genetics 176: 1151–1167.
- Greenland S (2009) Interactions in epidemiology: relevance, identification, and estimation. Epidemiology 20: 14–17.
- Zeng ZB, Wang T, Zou W (2005) Modeling 13 quantitative trait loci and interpretation of models. Genetics 169: 1711–1725.
- Jakulin A (2005) Machine learning based on attribute interaction. Ph.D. Dissertation. University of Liubliana. Sezana.
- Khoury MJ, Wacholder S (2009) Invited Commentary: From genome-wide association studies to gene-environment-wide interaction studies-challenges and opportunities. Am J Epidemiol 169: 227–230.

Found at: doi:10.1371/journal.pgen.1001131.s002 (0.07 MB XLS)

**Table S3** P-values for testing association of single SNP and interaction between two SNPs.

Found at: doi:10.1371/journal.pgen.1001131.s003 (0.08 MB XLS)

**Table S4** P-value for testing interaction calculated by T<sub>IH</sub>, PLINK and logistic regression using genotype coding.

Found at: doi:10.1371/journal.pgen.1001131.s004 (0.10 MB XLS)

Text S1 Appendices.

Found at: doi:10.1371/journal.pgen.1001131.s005 (0.06 MB DOC)

## Acknowledgments

The dataset(s) used for the analyses described in this manuscript were obtained from the database of Genotype and Phenotype (dbGaP) found at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number phs000019.v1.p1. Samples and associated phenotype data for the Collaborative Association Study of Psoriasis were provided by G.Abecasis. The authors thank three anonymous reviewers for insightful comments and suggestions.

#### **Author Contributions**

Conceived and designed the experiments: MX. Analyzed the data: XW HD LL YZ GP. Contributed reagents/materials/analysis tools: JDR. Wrote the paper: MX.

- An P, Mukherjee O, Chanda P, Yao L, Engelman CD, et al. (2009) The challenge of detecting epistasis (G G interactions): Genetic analysis workshop 16. Genet Epidem 33(Supplement 1): S58–S67.
- Zhao J, Jin L, Xiong MM (2006) Test for Interaction between Two Unlinked Loci. Am J Hum Genet 79: 831–845.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
   PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
- Curtis D (2007) Allelic association studies of genome wide association data can reveal errors in marker position assignments. BMC Genet 8: 30.
- Gayan J, González-Pérez A, Bermudo F, Sáez ME, Royo JL, et al. (2008) A
  method for detecting epistasis in genome-wide studies using case-control multilocus association analysis. BMC Genomics 9: 360.
- Emily M, Mailund T, Schauser L, Schierup MH (2009) Using biological networks to search for interacting loci in genome wide association studies. Eur J Hum Genet 17: 1231–1240.
- Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, et al. (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27: 29–34.
- Li W, Reich J (2000) A complete enumeration and classification of two-locus disease models. Hum. Hered 50: 334

  –349.
- Lehmann EL (1983) Theory of point estimation. John Wiley & Sons, Inc. New York.
- Piegorsch WW, Weinberg CR, Taylor JA (1994) Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med 13: 153–162.
- Yang Q, Khoury MJ, Sun F, Flanders WD (1999) Case-only design to measure gene-gene interaction. Epidemiology 10: 167–170.
- Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, et al. (2003) A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet 35: 349–356.
- Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, et al. (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78: 827–851.
- Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, et al. (2007) A largescale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80: 273–290.
- Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B (Methodological) 57: 289–300.



- 33. Lazova R, Gould Rothberg BE, Rimm D, Scott G (2009) The semaphorin 7A receptor Plexin C1 is lost during melanoma metastasis. Am J Dermatopathol 31:
- 34. Wang ZW, Fang YR, Hong W, Wang DX, Jing SD (2005) Association study of NOTCH4 gene polymorphisms with schizophrenia and mood disorders in mixed pedigrees. Yi Chuan 27: 865–868.
- 35. Meschia JF, Brott TG, Brown RD, Jr., Crook R, Worrall BB, et al. (2005) Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Ann Neurol 58: 351-361.
- Pedrosa E, Nolan KA, Stefanescu R, Hershcovitz P, Novak T, et al. (2009) Analysis of a promoter polymorphism in the SMDF neuregulin 1 isoform in Schizophrenia. Neuropsychobiology 59: 205–212.
- 37. Sethupathy P, Collins FS (2008) MicroRNA target site polymorphisms and human disease. Trends Genet 24: 489-4 97.
- 38. Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, et al. (2007) Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci U S A 104: 17016-17021.
- 39. Dai Y, Sui W, Lan H, Yan Q, Huang H, et al. (2009) Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int 29: 749-754.
- 40. Wang G, Van der Walt JM, Mayhew G, Li YJ, Züchner S, et al. (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 82: 283-289.
- 41. Li J, Ji L (2005) Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 95: 221–227.